SESSION TITLE: Lung Cancer IV
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: NSCLC is one of the severest malignancies dangerous for human’s health, whose morbidity and mortality are both highly increasing in all countries. Operative resection and postoperative adjuvant treatment are the best choice. The effect of adjuvant treatment depends on imaging tests. However, the patient was already in stage IV when recurrences or metastases were found by imaging tests. There are few successful treatment options for stage IV patients and the 5-year survival rate is less than 2%. Therefore, an early indicator on monitoring the therapeutic effects during adjuvant therapy for postoperative NSCLC patients is in need. Studies have showed that CTCs of peripheral blood is an important factor leading to disease progression and exacerbation, and could have diagnostic value in early stage of lung cancer. Therefore, we put forward hypothesis that EpCAM in CTCs in the peripheral blood can be an early indicator on monitoring the therapeutic effects during adjuvant therapy for postoperative NSCLC patients.